Ability of human umbilical cord mesenchymal stem cells to repair chemotherapy-induced premature ovarian failure.

Chemotherapy Endocrine function Ovarian injury Premature ovarian failure Repair Umbilical cord mesenchymal stem cells

Journal

World journal of stem cells
ISSN: 1948-0210
Titre abrégé: World J Stem Cells
Pays: United States
ID NLM: 101535826

Informations de publication

Date de publication:
26 Apr 2020
Historique:
received: 01 12 2019
revised: 19 03 2020
accepted: 26 03 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 14 5 2020
Statut: ppublish

Résumé

Premature ovarian insufficiency (POI) and premature ovarian failure (POF) have become one of the major problems threatening women of childbearing age. Studies have shown that stem cells transplanted from bone marrow, umbilical cord, peripheral blood and amniotic fluid can migrate and proliferate to the ovary, promote ovarian function repair, increase the number of follicles and granulosa cells at all levels of ovary, improve endocrine function, and can differentiate into oocytes in specific ovarian environment to restore fertility to some extent. To study the ability of human umbilical cord mesenchymal stem cells (hUCMSCs) to repair ovarian injury after chemotherapy. A total of 110 female BALB/c mice (aged 7-8 wk old) with body masses of 16.0-20.0 g were selected. The mice were fed until 12 wk of age, and cyclophosphamide was administered by intraperitoneal injection for 14 consecutive days to induce premature ovarian failure in mice. Seventy-five mice with estrous cycle disorder were screened and randomly divided into 3 groups according to their body weight: model group, positive control group and hUCMSC group, and each group had 25 mice. Another 25 mice were used as negative controls. The mice in the hUCMSC group were injected with hUCMSCs in the tail vein, and the mice in the positive control group were given an oestradiol valerate solution and a medroxyprogesterone acetate solution in the tail vein. On the 1 The estrous cycles of the model group mice were disrupted throughout the experiment. Mice in the hUCMSC group and the positive control group resumed normal estrous cycles. The ovarian weight of the model group mice continued to decline. The ovarian weight of the hUCMSC group mice and the positive control group mice decreased first and then gradually increased, and the ovarian weight of the hUCMSC group mice was heavier than that of the positive control group mice. The difference was statistically significant ( hUCMSCs can repair ovarian tissue damaged by chemotherapy to a certain extent, can improve the degree of apoptosis in ovarian tissue, and can improve the endocrine function of mouse ovaries.

Sections du résumé

BACKGROUND BACKGROUND
Premature ovarian insufficiency (POI) and premature ovarian failure (POF) have become one of the major problems threatening women of childbearing age. Studies have shown that stem cells transplanted from bone marrow, umbilical cord, peripheral blood and amniotic fluid can migrate and proliferate to the ovary, promote ovarian function repair, increase the number of follicles and granulosa cells at all levels of ovary, improve endocrine function, and can differentiate into oocytes in specific ovarian environment to restore fertility to some extent.
AIM OBJECTIVE
To study the ability of human umbilical cord mesenchymal stem cells (hUCMSCs) to repair ovarian injury after chemotherapy.
METHODS METHODS
A total of 110 female BALB/c mice (aged 7-8 wk old) with body masses of 16.0-20.0 g were selected. The mice were fed until 12 wk of age, and cyclophosphamide was administered by intraperitoneal injection for 14 consecutive days to induce premature ovarian failure in mice. Seventy-five mice with estrous cycle disorder were screened and randomly divided into 3 groups according to their body weight: model group, positive control group and hUCMSC group, and each group had 25 mice. Another 25 mice were used as negative controls. The mice in the hUCMSC group were injected with hUCMSCs in the tail vein, and the mice in the positive control group were given an oestradiol valerate solution and a medroxyprogesterone acetate solution in the tail vein. On the 1
RESULTS RESULTS
The estrous cycles of the model group mice were disrupted throughout the experiment. Mice in the hUCMSC group and the positive control group resumed normal estrous cycles. The ovarian weight of the model group mice continued to decline. The ovarian weight of the hUCMSC group mice and the positive control group mice decreased first and then gradually increased, and the ovarian weight of the hUCMSC group mice was heavier than that of the positive control group mice. The difference was statistically significant (
CONCLUSION CONCLUSIONS
hUCMSCs can repair ovarian tissue damaged by chemotherapy to a certain extent, can improve the degree of apoptosis in ovarian tissue, and can improve the endocrine function of mouse ovaries.

Identifiants

DOI: 10.4252/wjsc.v12.i4.277 PMID: 32399136 PMC: PMC7202924
pubmed: 32399136
doi: 10.4252/wjsc.v12.i4.277
pmc: PMC7202924
doi:

Types de publication

Journal Article

Langues

eng

Pagination

277-287

Informations de copyright

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: No conflict of interest.

Références

Stem Cells. 2006 May;24(5):1294-301
pubmed: 16410387
Cell Tissue Bank. 2016 Mar;17(1):123-36
pubmed: 26154770
J Intern Med. 2007 Nov;262(5):509-25
pubmed: 17949362
PLoS One. 2014 Oct 13;9(10):e108343
pubmed: 25310678
J Transl Int Med. 2018 Mar 28;6(1):32-37
pubmed: 29607302
Lancet. 2010 Sep 11;376(9744):911-21
pubmed: 20708256
Int J Mol Med. 2006 Dec;18(6):1089-96
pubmed: 17089012
Stem Cell Rev Rep. 2018 Feb;14(1):1-12
pubmed: 28884412
Cytotherapy. 2008;10(4):353-63
pubmed: 18574768
J Transl Int Med. 2018 Oct 09;6(3):128-133
pubmed: 30425948
Tissue Eng. 2007 Jan;13(1):111-21
pubmed: 17518585
Tissue Cell. 2016 Aug;48(4):370-82
pubmed: 27233913
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
J Midlife Health. 2015 Oct-Dec;6(4):147-53
pubmed: 26903753
J Endocrinol Invest. 2016 Sep;39(9):983-90
pubmed: 27091671
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
J Reprod Infertil. 2013 Jan;14(1):23-8
pubmed: 23926557
J Transl Int Med. 2018 Jun 26;6(2):70-73
pubmed: 29984200
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Nov;36(11):808-13
pubmed: 24507390
Stem Cells Int. 2016;2016:6901286
pubmed: 27651799
Stem Cell Res Ther. 2017 Aug 14;8(1):187
pubmed: 28807003
J Assist Reprod Genet. 2018 Jan;35(1):3-16
pubmed: 28932969
Mitochondrion. 2014 Nov;19 Pt A:105-12
pubmed: 25034305
Biomed Res Int. 2017;2017:8760383
pubmed: 28261617
Dig Dis. 2014;32 Suppl 1:50-60
pubmed: 25531353
Biofactors. 2017 Sep 10;43(5):633-644
pubmed: 28718997
Genes (Basel). 2016 Dec 13;7(12):
pubmed: 27983607
Biomed Pharmacother. 2018 Jun;102:254-262
pubmed: 29567538
Exp Neurol. 2010 Jun;223(2):267-81
pubmed: 19699201
Neural Regen Res. 2013 Aug 5;8(22):2093-102
pubmed: 25206518

Auteurs

Jian Shen (J)

Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command (Heping Campus), Shenyang 110000, Liaoning Province, China.

Dai Cao (D)

Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command (Heping Campus), Shenyang 110000, Liaoning Province, China.

Jing-Li Sun (JL)

Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command (Heping Campus), Shenyang 110000, Liaoning Province, China. zg3416@sina.com.

Classifications MeSH